Generic Loreev XR Availability
Last updated on Nov 8, 2022.
LOREEV XR (lorazepam - capsule, extended release;oral)
Approval date: August 27, 2021
Strength(s): 1MG [RLD], 2MG [RLD], 3MG [RLD]
Approval date: February 16, 2022
Strength(s): 1.5MG [RLD]
Has a generic version of Loreev XR been approved?
No. There is currently no therapeutically equivalent version of Loreev XR available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Loreev XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Sustained release formulations of lorazepam
Issued: April 7, 2015
Assignee(s): Edgemont Pharmaceuticals LLC
A pharmaceutical composition for delivering lorazepam in a prolonged fashion is achieved with prolonged release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam beads and delayed sustained release lorazepam beads. The composition can provide once daily dosing that maintains 24 hour therapeutic effect under steady state conditions.
Patent expiration dates:
- January 8, 2034✓✓
- January 8, 2034
More about Loreev XR (lorazepam)
- Check interactions
- Pricing & coupons
- Reviews (1)
- Drug images
- Latest FDA alerts (5)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: benzodiazepines
- En español
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.